• Xiaolin Lu and Dongzhi Zhang.
• Department of Orthopedic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
• World Neurosurg. 2023 Nov 1; 179: e582e592e582-e592.

ObjectiveGlioma is one of the leading causes of death in patients with intracranial tumours. RPL34 divergent transcript (RPL34-DT) is a long non-coding ribonucleic acid that is significantly upregulated in glioma tissues. However, the role of RPL34-DT in glioma behavior remains to be elucidated. Therefore, in this study, we focused on the effect of RPL34-DT on the epithelial-mesenchymal transition in gliomas.MethodsReal-time quantitative reverse transcription polymerase chain reaction was used to detect the levels of RPL34-DT in glioma tissue and cell lines. We further used the LN229 and U251 glioma cell lines to assess the role of RPL34-DT. Wound healing and invasion assays were performed to determine the role of RPL34-DT in migration. Changes in protein levels were assessed by western blotting.ResultsWe found that RPL34-DT was upregulated in glioma tissues and glioma cell lines. Knockdown of RPL34-AS1 blocked migration of glioma cell. This effect occurred through a decrease of epithelial-mesenchymal transition and β-catenin.ConclusionsThis study suggests that RPL34-DT affects cell migration in glioma and therefore may serve as a valuable therapeutic target in patients with glioma.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

22 keywords...

hide…